Discounted Cash Flow (DCF) Analysis Levered
BiondVax Pharmaceuticals Ltd. (BVXV)
$1.36
+0.01 (+0.74%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | - | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
Share price | $ 1.36 |
---|---|
Beta | 2.366 |
Diluted Shares Outstanding | 754,076.41 |
Cost of Debt | |
Tax Rate | 90.84 |
After-tax Cost of Debt | -2.24% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 15.788 |
Total Debt | 21.54 |
Total Equity | 1,025,543.91 |
Total Capital | 1,025,565.46 |
Debt Weighting | 0.00 |
Equity Weighting | 100.00 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | - | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
WACC | ||||||||||
PV LFCF | - | - | - | - | - | - | ||||
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 15.79 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | 7.47 |
Equity Value | - |
Shares Outstanding | 754,076.41 |
Equity Value Per Share | - |